The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule ...

Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...

CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 / Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a ...

AN9025 is an oral small molecule pan-RAS(ON) inhibitor with best-in-class potential, designed to target a broad spectrum of RAS mutations across various tumor types. Preclinical studies have ...

Efficacy assessment of a novel pan-RAS inhibitor in KRAS-mutant and wild type colorectal 3D bioprinted organoid tumor tissue. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...

Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost ...

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, ...

Erasca (NASDAQ:ERAS) executives outlined the company’s strategy to target RAS-driven cancers and previewed upcoming clinical ...